Defkot API

Name	Defkot
Chinese name	地夫可特
Cas Number	14484-47-0
Source	Europe
Qualifications	USDMF/-/-/-/-

Difcote is a third-generation steroidal glucocorticoid drug developed by Marathon Pharmaceuticals and approved by the US FDA in February 2017 for the treatment of Duchenne muscular dystrophy. Difcod is rapidly metabolized into active 21-OH difcod, which exhibits anti-inflammatory and immunosuppressive effects by acting on glucocorticoid receptors. Clinical studies have shown that the potency ratio of difcote to prednisolone is 0.69-0.89. Compared with other glucocorticoids, Difcote is effective in treating rheumatoid arthritis and systemic lupus erythematosus. Compared with other glucocorticoids, it has an earlier and longer-lasting effect; and its side effects, especially in promoting the excretion of calcium in the urine and inhibiting The intestinal absorption of calcium is weaker than that of prednisolone acetate and betamethasone, and the side effects on bone loss are weaker. As a third-generation glucocorticoid, Difcote has stable efficacy and low side effects. Its sales have been stable since its launch. Global sales in 2014 were US$93.88 million, and it was approved by the US FDA for the treatment of Duchenne muscular dystrophy. , Its sales promotion will play a very useful role in promoting.

Hot Tags: defkot api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lercanidipine Hydrochloride API, Vinpocetine API, Letrozole API, Clofarabine API, Lapatinib Ditosylate API, Gabapentin API

• Previous: Lenatinib Maleate/neratinib Maleate API
• Next: Dolutegravir Sodium API